GeneCast Biotechnology Co., Ltd.
19
4
6
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
5.3%
1 terminated/withdrawn out of 19 trials
50.0%
-36.5% vs industry average
21%
4 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Role: collaborator
Adjuvant Pancreatic Therapy Guided by MRD
Role: collaborator
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer
Role: collaborator
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
Role: collaborator
Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)
Role: lead
Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Role: collaborator
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
Role: collaborator
Hepatobiliary Tumors Tissue Samples Acquisition
Role: collaborator
Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy
Role: collaborator
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
Role: collaborator
Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA
Role: lead
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Role: collaborator
Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer
Role: collaborator
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Role: collaborator
Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Role: collaborator
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
Role: collaborator
Multi-Omics Noninvasive Inspection of TumOr Risk for Gastric Cancer
Role: lead
Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC
Role: collaborator
Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
Role: collaborator
All 19 trials loaded